关注
Frederic Bouder
标题
引用次数
引用次数
年份
The COVID-19 pandemic: how can risk science help?
T Aven, F Bouder
Journal of Risk Research 23 (7-8), 849-854, 2020
1222020
The tolerability of Risk
F Bouder, D Slavin, RE Lofstedt
A New Framework for Risk Management. London: Earthscan, 2007
1202007
The changing nature of communication and regulation of risk in Europe
R Lofstedt, F Bouder, J Wardman, S Chakraborty
Journal of Risk Research 14 (4), 409-429, 2011
1102011
Transparency in Europe: a quantitative study
F Bouder, D Way, R Löfstedt, D Evensen
Risk Analysis 35 (7), 1210-1229, 2015
752015
New transparency policies: Risk communication's doom?
RE Löfstedt, F Bouder
Effective risk communication, 73-90, 2013
412013
Evidence-based uncertainty analysis: What should we now do in Europe? A view point
R Lofstedt, F Bouder
Journal of Risk Research 24 (5), 521-540, 2021
402021
Regulating impurities in pharmaceutical products: a tolerability of risk approach?
F Bouder
Expert Review of Clinical Pharmacology 1 (2), 241-250, 2008
402008
The Potsdam radon communication manifesto
F Bouder, T Perko, R Lofstedt, O Renn, C Rossmann, D Hevey, M Siegrist, ...
Journal of Risk Research 24 (7), 909-912, 2021
302021
Varieties of risk regulation in Europe: coordination, complementarity and occupational safety in capitalist welfare states
H Rothstein, D Demeritt, R Paul, AL Beaussier, M Wesseling, M Howard, ...
Socio-Economic Review 17 (4), 993-1020, 2019
292019
Pharmaceutical benefit–risk communication tools: a review of the literature
D Way, H Blazsin, R Löfstedt, F Bouder
Drug safety 40, 15-36, 2017
292017
Medicines transparency at the European Medicines Agency (EMA) in the new information age: the perspectives of patients
D Way, F Bouder, R Löfstedt, D Evensen
Journal of Risk Research 19 (9), 1185-1215, 2016
272016
Risk communication of vaccines: challenges in the post-trust environment
F Bouder
Current drug safety 10 (1), 9-15, 2015
202015
When ‘must’means ‘maybe’: varieties of risk regulation and the problem of trade-offs in Europe
H Rothstein, AL Beaussier, O Borraz, F Bouder, D Demeritt, M de Haan, ...
HowSAFE WP 1, 15, 2015
152015
The future of risk communication and the role of the pharmaceutical industry
S Chakraborty, F Bouder
Current drug safety 8 (1), 4-10, 2013
152013
Effects of public trust on behavioural intentions in the pharmaceutical sector: data from six European countries
D Balog-Way, D Evensen, R Löfstedt, F Bouder
Journal of Risk Research 24 (6), 645-672, 2021
142021
Risk-based governance against national obstacles? Comparative dynamics of Europeanization in Dutch, French, and German flooding policies
R Paul, F Bouder, M Wesseling
Journal of Risk Research 19 (8), 1043-1062, 2016
142016
Transparency and the Food and Drug Administration—A quantitative study
R Lofstedt, F Bouder, S Chakraborty
Journal of health communication 18 (4), 391-396, 2013
142013
Governance for sustainable development in Canada
F Bouder
Governance for Sustainable Development: Five OECD Case Studies, Paris: OECD, 2001
122001
Benefit/risk communication by the European Medicines Agency: a study of influential stakeholders' expectations and attitudes
F Bouder
European Medicines Agency (EMA), 2011
112011
Prioritizing polio
B Rath, M Ali, C Elemuwa, W Maurer, F Bouder, E Mworozi, S Diedrich, ...
Expert review of vaccines 11 (12), 1389-1392, 2012
102012
系统目前无法执行此操作,请稍后再试。
文章 1–20